{"clinical_study": {"@rank": "222", "required_header": {"download_date": "ClinicalTrials.gov processed this data on April 02, 2020", "link_text": "Link to the current ClinicalTrials.gov record.", "url": "https://clinicaltrials.gov/show/NCT04306393"}, "id_info": {"org_study_id": "NO-SARS-COVID-19", "nct_id": "NCT04306393"}, "brief_title": "Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19", "acronym": "NOSARSCOVID", "official_title": "Nitric Oxide Gas Inhalation Therapy for Mechanically Ventilated Patients With Severe Acute Respiratory Syndrome Caused by SARS-CoV2: a Randomized Clinical Trial.", "sponsors": {"lead_sponsor": {"agency": "Massachusetts General Hospital", "agency_class": "Other"}, "collaborator": [{"agency": "Xijing Hospital", "agency_class": "Other"}, {"agency": "Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico", "agency_class": "Other"}, {"agency": "Niguarda Hospital", "agency_class": "Other"}]}, "source": "Massachusetts General Hospital", "oversight_info": {"has_dmc": "Yes", "is_fda_regulated_drug": "Yes", "is_fda_regulated_device": "No", "is_us_export": "No"}, "brief_summary": {"textblock": "Severe acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related\n      infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to\n      refractory hypoxemia. To date, there is no specific treatment available for 2019-nCoV. Nitric\n      oxide is a selective pulmonary vasodilator gas used in as a rescue therapy in refractory\n      hypoxemia due to acute respiratory distress syndrome (ARDS). In-vitro and clinical evidence\n      indicate that inhaled nitric oxide gas (iNO) has also antiviral activity against other\n      strains of coronavirus. The primary aim of this study is to determine whether inhaled NO\n      improves oxygenation in patients with hypoxic SARS-CoV2. This is a multicenter single-blinded\n      randomized controlled trial with 1:1 individual allocation"}, "detailed_description": {"textblock": "Severe acute respiratory syndrome (SARS-CoV-2) due to novel Coronavirus (2019-nCoV) related\n      infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to\n      refractory hypoxemia. To date, there is no specific treatment available for 2019-nCoV. Nitric\n      oxide is a selective pulmonary vasodilator gas used as a rescue therapy in refractory\n      hypoxemia due to acute respiratory distress syndrome (ARDS). In has also shown in-vitro and\n      clinical evidence that inhaled nitric oxide gas (iNO) has antiviral activity against other\n      strains of coronavirus.\n\n      The primary aim of this study is to determine whether inhaled NO improves oxygenation in\n      patients with hypoxic SARS-CoV2.\n\n      This is a multicenter randomized controlled trial with 1:1 individual allocation. Patients\n      will be blinded to the treatment.\n\n      Intubated patients admitted to the intensive care unit with confirmed SARS-CoV-2 infection\n      and severe hypoxemia will be randomized to receive inhalation of NO (treatment group) or not\n      (control group). Treatment will be stopped when patients are free from hypoxemia for more\n      than 24 hours."}, "overall_status": "Recruiting", "start_date": {"@type": "Actual", "#text": "March 21, 2020"}, "completion_date": {"@type": "Anticipated", "#text": "March 21, 2022"}, "primary_completion_date": {"@type": "Anticipated", "#text": "March 21, 2021"}, "phase": "Phase 2", "study_type": "Interventional", "has_expanded_access": "No", "study_design_info": {"allocation": "Randomized", "intervention_model": "Parallel Assignment", "primary_purpose": "Treatment", "masking": "Single (Participant)", "masking_description": "The patient is blinded to the treatment."}, "primary_outcome": {"measure": "Change of arterial oxygenation at 48 hours from enrollment", "time_frame": "48 hours", "description": "Difference within groups in terms of PaO2/FiO2 ratio. If a patient dies during the first 48 hours of treatment, the last available blood gas analysis will be used."}, "secondary_outcome": [{"measure": "Time to reach normoxemia during the first 28 days after enrollment", "time_frame": "28 days", "description": "Time to recover gas exchange to a PaO2/FiO2 =/> 300 for at least 24 hours during the first 28 days after enrollment, within each group and comparison between groups. If the patient dies before day 28, the patient will be considered as \"never recovered\"."}, {"measure": "Proportion of SARS-nCoV-2 free patients during the first 28 days after enrollment", "time_frame": "28 days", "description": "Daily proportion of patients with a PaO2/FiO2 ratio > 300 for at least 24 hours within each group and comparison between groups. If a patient dies before day 28, the patient will be considered as \"never recovered\"."}, {"measure": "Survival at 28 days from enrollment", "time_frame": "28 days", "description": "Proportion of patients surviving at 28 days within each group and comparison between groups."}, {"measure": "Survival at 90 days from enrollment", "time_frame": "90 days", "description": "Proportion of patients surviving at 90 days within each group and comparison between groups."}], "other_outcome": [{"measure": "Daily oxygenation in the two groups until day 28", "time_frame": "28 days", "description": "Expressed as PaO2/FiO2 ratio within each group and comparison between groups."}, {"measure": "Need for new renal replacement therapy during the first 28 days", "time_frame": "28 days", "description": "Proportion of patients needing RRT within each group and comparison between groups."}, {"measure": "Mechanical support of circulation during the first 28 days", "time_frame": "28 days", "description": "Proportion of patients needing (i.e., ECMO, intra-aortic balloon pump, VADs) within each group and comparison between groups."}, {"measure": "Days free of vasopressors during the first 28 days", "time_frame": "28 days", "description": "Average days without need for vasopressors within each group and comparison between groups."}, {"measure": "Ventilator-free day at 28 days", "time_frame": "28 days", "description": "Average days without need for mechanical ventilation within each group and comparison between groups."}, {"measure": "Time to SARS-CoV-2 rt-PCR negative in upper respiratory tract specimen", "time_frame": "28 days", "description": "Time to obtain first negative upper respiratory trait sample in the 2019-nCoV rt-PCR assay. Average within groups and comparison between groups."}, {"measure": "ICU-free days at 28 days", "time_frame": "28 days", "description": "Average days out of ICU within each group and comparison between groups."}, {"measure": "ICU length of stay", "time_frame": "90 days", "description": "Average days of ICU admission within each group and comparison between groups."}], "number_of_arms": "2", "enrollment": {"@type": "Anticipated", "#text": "200"}, "condition": ["SARS (Severe Acute Respiratory Syndrome)", "Coronavirus"], "arm_group": [{"arm_group_label": "Treatment Group", "arm_group_type": "Experimental", "description": "Inhaled Nitric Oxide until PaO2/FiO2 >/= 300 mmHg"}, {"arm_group_label": "Control Group", "arm_group_type": "No Intervention"}], "intervention": {"intervention_type": "Drug", "intervention_name": "Nitric Oxide Gas", "description": "80 ppm of inhaled nitric oxide for 48 hours, followed by 40 ppm, followed by weaning before stop.\nWeaning criteria: maintenance of a PaO2/FiO2 ratio >/= 300 for at least 24 hours consecutively.", "arm_group_label": "Treatment Group"}, "eligibility": {"criteria": {"textblock": "Inclusion Criteria:\n\n          -  >/= 18 years old\n\n          -  ICU admission\n\n          -  Intubation and mechanical ventilation\n\n          -  Positivity of 2019-nCoV rt-PCR\n\n          -  PaO2/FiO2 ratio < 300 mmHg\n\n        Exclusion Criteria:\n\n          -  patients intubated for 72 hours or more from initiation of the treatment gas\n\n          -  physician being contrary to the involvement as participating in the trial is not in\n             the patient's best interest, or any condition that does not allow the protocol to be\n             followed safely\n\n          -  pregnancy"}, "gender": "All", "minimum_age": "18 Years", "maximum_age": "99 Years", "healthy_volunteers": "No"}, "overall_official": {"last_name": "Lorenzo Berra, MD", "role": "Study Director", "affiliation": "Massachusetts General Hospital"}, "overall_contact": {"last_name": "Lorenzo Berra, MD", "phone": "+16176437733", "email": "lberra@mgh.harvard.edu"}, "overall_contact_backup": {"last_name": "Chong Lei, MD, PhD", "phone": "+8618629011362", "email": "crystalleichong@126.com"}, "location": {"facility": {"name": "Massachusetts General Hospital", "address": {"city": "Boston", "state": "Massachusetts", "zip": "02114", "country": "United States"}}, "status": "Recruiting", "contact": {"last_name": "Lorenzo Berra, MD"}}, "location_countries": {"country": "United States"}, "verification_date": "March 2020", "study_first_submitted": "March 10, 2020", "study_first_submitted_qc": "March 10, 2020", "study_first_posted": {"@type": "Actual", "#text": "March 12, 2020"}, "last_update_submitted": "March 21, 2020", "last_update_submitted_qc": "March 21, 2020", "last_update_posted": {"@type": "Actual", "#text": "March 24, 2020"}, "responsible_party": {"responsible_party_type": "Principal Investigator", "investigator_affiliation": "Massachusetts General Hospital", "investigator_full_name": "Lorenzo Berra, MD", "investigator_title": "Medical Doctor"}, "condition_browse": {"mesh_term": ["Coronavirus Infections", "Severe Acute Respiratory Syndrome", "Syndrome"]}, "intervention_browse": {"mesh_term": "Nitric Oxide"}, "patient_data": {"sharing_ipd": "No"}}}